Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.83 |
| ▸ | IGF1R | P08069 | 10/20 | 0.77 |
| ▸ | INSR | P06213 | 9/20 | 0.77 |
| ▸ | IKBKB | O14920 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | CHUK | O15111 | 1/20 | 0.64 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.64 |
| ▸ | PAK3 | O75914 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | FES | P07332 | 1/20 | 0.64 |
| ▸ | HCK | P08631 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | INSRR | P14616 | 1/20 | 0.64 |
| ▸ | FER | P16591 | 1/20 | 0.64 |
| ▸ | FLT4 | P35916 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310704 | 0.98 | IGF1R (0.81) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL310553 | 0.95 | EGFR (0.79) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL310797 | 0.95 | IGF1R (0.83) | EGFRERBB2IGF1RINSR | |
| SCHEMBL310742 | 0.93 | IGF1R (0.86) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL10290241 | 0.93 | EGFR (0.72) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL310544 | 0.93 | IGF1R (0.74) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL310985 | 0.93 | INSR (0.78) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL10257301 | 0.92 | EGFR (0.72) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL311070 | 0.92 | IGF1R (0.91) | EGFRERBB2IGF1RINSRIKBKB | |
| SCHEMBL10290733 | 0.91 | IGF1R (0.76) | EGFRERBB2IGF1RINSRIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | EGFR 491/4885ERBB2 55/4885IGF1R 633/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | EGFR 491/4885ERBB2 55/4885IGF1R 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.